Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies

Sponsor
Oslo University Hospital
Study ID
NCT02073500
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Observational study. — OTHER
    Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor. HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease.

Study Details

The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).

Key Dates

First listed
Feb 27, 2014
Start date
Sep 30, 2009
Status verified
Jul 2021
Primary completion
Aug 31, 2022
Completion
Aug 31, 2027

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Observational study
    Patients diagnosed with PSM undergoing CRS with HIPEC.

Primary Outcome Measure

Overall survival (OS) [ Time Frame: 5 years ]

Central Contacts

Find similar trials

Nationwide
Colorectal cancer trialsOvarian cancer trialsOncology trialsGI oncology trialsGynecologic oncology trialsWomen's health trials

Related Studies